Literature DB >> 9449379

Lentiviral vectors for gene therapy of cystic fibrosis.

M J Goldman1, P S Lee, J S Yang, J M Wilson.   

Abstract

A replication-defective vector based on human immunodeficiency virus (HIV) was evaluated for gene transfer directed to the lung. The tropism of this vector has been expanded through the incorporation of the vesticular stomatitis virus G protein into its envelope. The HIV vector effectively transduced nondividing airway epithelial cells in vitro whereas a murine-based retroviral vector did not. Experiments in a human bronchial xenograft model demonstrated high-level gene transduction with a cystic fibrosis transmembrane conductance regulator (CFTR) HIV vector into undifferentiated, cystic fibrosis (CF)-derived cells of the xenograft. CFTR expression was stable and capable of functional correction of the CF defect after the graft matured. The HIV vector did not effectively transduce cells of the xenograft when instilled after the epithelium had differentiated. This block to transduction appears to be at the level of entry, although post entry restrictions cannot be ruled out. Further development of this vector system for CF gene therapy should focus on a better understanding of potential entry and post entry blocks.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9449379     DOI: 10.1089/hum.1997.8.18-2261

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  34 in total

1.  Bad for cats, good for humans? Modified feline immunodeficiency virus for gene therapy.

Authors:  R G Crystal
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Status of gene therapy for cystic fibrosis lung disease.

Authors:  R C Boucher
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

3.  Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.

Authors:  M Sena-Esteves; Y Saeki; S M Camp; E A Chiocca; X O Breakefield
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

5.  Lentiviral transfection of ependymal primary cultures facilitates the characterisation of kinocilia-specific promoters.

Authors:  Bhavani S Kowtharapu; Franklin C Vincent; Andreas Bubis; Stephan Verleysdonk
Journal:  Neurochem Res       Date:  2009-02-04       Impact factor: 3.996

6.  Retrovirus vectors bearing jaagsiekte sheep retrovirus Env transduce human cells by using a new receptor localized to chromosome 3p21.3.

Authors:  S K Rai; J C DeMartini; A D Miller
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells.

Authors:  D S An; R P Wersto; B A Agricola; M E Metzger; S Lu; R G Amado; I S Chen; R E Donahue
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

9.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

10.  Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals.

Authors:  Dana Willner; Mike Furlan; Matthew Haynes; Robert Schmieder; Florent E Angly; Joas Silva; Sassan Tammadoni; Bahador Nosrat; Douglas Conrad; Forest Rohwer
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.